
Publication
Government of Alberta launches nuclear energy engagement
On August 25, 2025, the Government of Alberta publicly re-affirmed its interest in nuclear energy with the launch of its Nuclear Energy Engagement (the Engagement).
Global | Publication | February 2024
We are pleased to introduce you to an archive of the International Restructuring Newswire. The publication collects the latest news and trends from our team of bankruptcy and insolvency lawyers from around the globe providing the latest developments on cross-border restructuring and insolvency cases.
Howard Seife David Rosenzweig
Global Head Partner
Financial Restructuring and Insolvency Editor, International Restructuring Newswire
International Restructuring Newswire
April 2023
International Restructuring Newswire
January 2023
International Restructuring Newswire
October 2022
International Restructuring Newswire
July 2022
International Restructuring Newswire
April 2022
International Restructuring Newswire
January 2022
International Restructuring Newswire
November 2021
International Restructuring Newswire
July 2021
International Restructuring Newswire
April 2021
International Restructuring Newswire
January 2021
International Restructuring Newswire
October 2020
International Restructuring Newswire
June 2020
International Restructuring Newswire
January 2020
International Restructuring Newswire
October 2019
International Restructuring Newswire
July 2019
International Restructuring Newswire
April 2019
International Restructuring Newswire
January 2019
International Restructuring Newswire
October 2018
Publication
On August 25, 2025, the Government of Alberta publicly re-affirmed its interest in nuclear energy with the launch of its Nuclear Energy Engagement (the Engagement).
Publication
Health Canada has proposed a major change to the regulation of biosimilar drugs that may accelerate biologic patent litigation in Canada. Following the lead of other jurisdictions, Health Canada has proposed that biosimilar manufacturers no longer be required to conduct phase 3 clinical trials to enter the Canadian market.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025